Patents by Inventor Kenneth N. Wills

Kenneth N. Wills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THYMIC REGENERATION AND T-CELL RECONSTITUTION
    Publication number: 20220226391
    Abstract: The present invention provides non-thymic endothelial cells (ntECs) engineered to express adenovirus E4ORF1 and/or BMP4, and compositions comprising such engineered ntECs. The present invention also provides methods of using such ntECs in therapy, for example to enhance thymic regeneration (including T cell reconstitution) in subjects in need thereof. Such subjects include those that have a damaged thymus, defective thymic function, insufficient T-cell output, and/or that are immunocompromised—for example as a result of ageing, infection (e.g. with HIV), treatment with radiation therapy, treatment with chemotherapy, or myeloablative conditioning in preparation for an organ/tissue transplant.
    Type: Application
    Filed: May 28, 2020
    Publication date: July 21, 2022
    Inventors: Kenneth N. Wills, Karolina Kucharova, Michael Daniel Ginsberg, Daniel Joseph Nolan, Paul William Finnegan
  • Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins
    Patent number: 6902731
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: June 7, 2005
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
  • Retinoblastoma fusion proteins
    Patent number: 6379927
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: April 30, 2002
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
  • Retinoblastoma fusion polypeptides
    Patent number: 6074850
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: June 13, 2000
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills